|
|
Benign Hyperplastic Prostates (n = 25)
|
Prostatic Adenocarcinoma (n = 25)
|
| Receptor |
Normal Prostates (n = 15) |
NH (n = 8) |
BCH (n = 8) |
AH (n = 9) |
WDA (n = 9) |
MDA (n = 8) |
PDA (n = 8) |
|
RXR  |
15 (100%) |
8 (100%) |
8 (100%) |
2 (22.5%) |
9 (100%) |
8 (100%) |
8 (100%) |
| RXR ß |
8 (53.3%) |
0 (0%) |
8 (100%) |
0 (0%) |
3 (33.3%) |
0 (0%) |
0 (0%) |
RXR  |
15 (100%) |
7 (87.5%) |
8 (100%) |
2 (22.5%) |
9 (100%) |
8 (100%) |
8 (100%) |
|
| *NH, nodular hyperplasia; BCH, basal cell hyperplasia; AH, atrophic
hyperplasia; WDA, well-differentiated adenocarcinoma; MDA,
moderate-differentiated adenocarcinoma; PDA, poorly differentiated
adenocarcinoma. |
|
